Probability of Developing Type 1 Diabetes

Type 1 diabetes affects approximately 1.6 million Americans, with about 64,000 new diagnoses per year. The lifetime risk is approximately 0.5% (1 in 200). While traditionally considered a childhood disease, about 50% of new diagnoses actually occur in adults. Incidence has been increasing by about 2-3% per year globally.

Type 1 diabetes is an autoimmune condition where the immune system destroys the insulin-producing beta cells of the pancreas. Unlike type 2 diabetes, it is not related to diet or lifestyle. Risk factors include family history (about 5% risk if a parent has it), certain HLA genotypes, and possibly environmental triggers (viral infections, early diet factors). Screening for islet autoantibodies can now identify at-risk individuals years before clinical onset.

Treatment requires lifelong insulin therapy, with most patients using either multiple daily injections or an insulin pump. Continuous glucose monitors (CGMs) and hybrid closed-loop insulin delivery systems ("artificial pancreas") have dramatically improved glucose management. The FDA approved teplizumab (Tzield) in 2022 as the first drug to delay type 1 diabetes onset in at-risk individuals. Life expectancy has improved but remains about 8-12 years shorter than the general population, primarily due to cardiovascular complications.